Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma

NCT07751744 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain Metastases From Solid Tumors
Leptomeningeal Disease
High Grade Glioma (HGG)
Glioblastoma (GBM)

Interventions

DRUG: JBI-778

Sponsor

Jubilant Therapeutics Inc.